MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate

C. F. Qu, Y. Li, Y. J. Song, S. M A Rizvi, C. Raja, D. Zhang, J. Samra, R. Smith, A. C. Perkins, C. Apostolidis, B. J. Allen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

102 Citations (Scopus)


Control of micrometastatic pancreatic cancer remains a major objective in pancreatic cancer treatment. The overexpression of MUC1 mucin plays an important role in cancer metastasis. The aim of this study was to detect the expression of MUC1 in human primary tumour tissues and three pancreatic cancer cell lines (CAPAN-1, CFPAC-1 and PANC-1), and target MUC1-positive cancer cells in vitro using 213Bi-C595 alpha-immunoconjugate (AIC). The expression of MUC1 on pancreatic tumour tissues and cancer cell lines was performed by immunohistochemistry and further confirmed by confocal microscope and flow cytometry analysis on the cell surface. Cytotoxicity of 213Bi-C595 was tested by MTS assay. Apoptosis was documented using TUNEL assay. Overexpression of MUC1 was found in ∼90% of tested tumour samples and the three pancreatic cancer cell lines. 2l3Bi-C595 is specifically cytotoxic to pancreatic cancer cells in a concentration-dependent fashion. These results suggest that overexpression of MUC1 in pancreatic cancer is a useful target, and that the novel 213Bi-C595 AIC selectively targets pancreatic cancer cells in vitro. 213Bi-C595 may be a useful agent for the treatment of micrometastases or minimal residual disease (MRD) in pancreatic cancer patients with overexpression of MUC1 antigen.

Original languageEnglish
Pages (from-to)2086-2093
Number of pages8
JournalBritish Journal of Cancer
Issue number12
Publication statusPublished - 13 Dec 2004


  • α-particle emitter Bi
  • C595 monoclonal antibody
  • MUC-1 mucin
  • Pancreatic cancer cell lines
  • Pancreatic tumours
  • Radioimmunoconjugate


Dive into the research topics of 'MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate'. Together they form a unique fingerprint.

Cite this